Annexon (ANNX)
(Delayed Data from NSDQ)
$4.75 USD
-0.35 (-6.86%)
Updated May 10, 2024 04:00 PM ET
After-Market: $4.75 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
F Value C Growth D Momentum D VGM
Annexon, Inc. (ANNX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$15.17 | $30.00 | $10.00 | 197.45% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for Annexon, Inc. comes to $15.17. The forecasts range from a low of $10.00 to a high of $30.00. The average price target represents an increase of 197.45% from the last closing price of $5.10.
Analyst Price Targets (6 )
Broker Rating
Annexon, Inc. currently has an average brokerage recommendation (ABR) of 1.13 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by eight brokerage firms. The current ABR compares to an ABR of 1.13 a month ago based on eight recommendations.
Of the eight recommendations deriving the current ABR, seven are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 87.5% and 12.5% of all recommendations. A month ago, Strong Buy made up 87.5%, while Buy represented 12.5%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 7 | 7 | 7 | 7 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.13 | 1.13 | 1.13 | 1.13 | 1.43 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
4/3/2024 | Cantor Fitzgerald & Co | Pete Stavropoulos | Strong Buy | Strong Buy |
3/4/2024 | Needham & Company | Joseph R Stringer | Moderate Buy | Moderate Buy |
3/4/2024 | H.C. Wainwright & Co. | Andrew S Fein | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.13 |
ABR (Last week) | 1.13 |
# of Recs in ABR | 8 |
Average Target Price | $15.17 |
LT Growth Rate | 9.80% |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.32 |